Alzheimer’s Experts: Lecanemab Is A Win, But Also Just The Beginning
CTAD Panelists Cheer Eisai/Biogen Data, Note Challenges Ahead
While Phase III results for Eisai and Biogen’s lecanemab show amyloid clearance provides benefit and Roche’s Phase III gantenerumab data are supportive, more data and certainty of access to treatment are needed.